Japan Non-Opioid Pain Patches Market

Japan Non-Opioid Pain Patches Market Insights Forecasts to 2035

• The Japan Non-Opioid Pain Patches Market Size Was Estimated at USD 35.4 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 5.46% from 2025 to 2035
• The Japan Non-Opioid Pain Patches Market Size is Expected to Reach USD 63.56 Million by 2035

According to a research report published by Decision Advisors & Consulting, the Japan Non-Opioid Pain Patches Market size is anticipated to reach USD 63.56 Million by 2035, growing at a CAGR of 5.46% from 2025 to 2035.  Japan Non-Opioid Pain Patches Market is growing due to an aging population experiencing more pain, an increased preference for non-invasive treatments over oral medications or Injection-based relief, along with increased awareness of the risk of opioid addiction, which continues to spur growth.

Market Overview

The Japan non-opioid pain patch market is a segment of the broader pain management market, driven by factors like Japan's aging population, high demand for effective and non-addictive pain relief, and the prevalence of chronic conditions such as arthritis and lower back pain. There is a clear trend towards a preference for local anaesthetics and NSAIDs, an increase in OTC medications, and a rapidly growing technological development of patch-based delivery systems by companies such as Hisamitsu Pharmaceutical that offer innovative transdermal products to the market. Strategic partnerships and increased use of online sales channels are additional opportunities for growth in the market. The Japan non-opioid pain patch market is driven by the country's aging population and the resulting increase in chronic pain conditions, the convenience and ease of transdermal patches, and a cultural emphasis on self-medication and self-care. The NSAID Patch market's key characteristics are anticipated to be characterized by a high demand for NSAID patches, increased overall sales growth at both retail and digital pharmacies, and emerging initiatives such as Advanced Drug Delivery Systems, Personalized Medicine, and the integration of Digital Health into traditional products and services.

Japanese regulatory agencies have recognized the growing demand for non-opioid pain management and are providing methods and support to stimulate the marketplace and to expedite the approval process for innovative therapies. The Sakigake program is a Japan Ministry of Health, Labour and Welfare (MHLW) initiative similar to the US FDA’s (Food and Drug Administration) Breakthrough Therapy designation for fast-tracking drug development and evaluation for serious or life-threatening diseases with unmet medical needs.

Report Coverage

This research report categorizes the market for the Japan non-opioid pain patch market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan non-opioid pain patch market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan non-opioid pain patch market.

Driving Factor

The Japan non-opioid pain patch market is driven by a growing elderly population, prone to chronic conditions like arthritis and neuropathic pain, which is driving increased demand for effective pain management solutions. Patients and healthcare providers increasingly prefer non-invasive, localized treatments such as patches due to their convenience, ease of use, and reduced systemic side effects. Rising awareness of opioid-related risks is boosting demand for safer alternatives.

Restraining Factor

The non-opioid pain patch market in Japan is restrained by high development and production costs, complex regulatory requirements, and intense competition, while issues like patient adherence, limited market reach, and cultural differences in treatment practices further restrain growth.

Market Segmentation

The Japan non-opioid pain patches market share is categorized by patch type and technology.

• The lidocaine patches segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan non-opioid pain patches market is segmented by patch type into lidocaine patches, diclofenac patches, capsaicin patches, and other. Among these, the lidocaine patches segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth is driven by the growing need for non-opioid therapies to manage acute and chronic pain. With the aging population continuing to increase, there will be a need for an alternative method of treating those patients. The current state of awareness regarding alternative pain therapies has led to an increase in the demand for alternative treatment methods.

• The matrix patches segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan non-opioid pain patches market is segmented by technology into matrix patches, reservoir patches, and others. Among these, the matrix patches segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth is driven by the innovative technology that provides flexibility in the development of various Active Pharmaceutical Ingredients (APIs) and consistent release profiles over an extended period of time, much like the release profile of nicotine patches that are used to quit smoking. Continued advances in regenerative medicine, as well as growing demand for effective tissue repair solutions for conditions associated with cardiovascular disease and diabetic foot ulcers, have increased the potential for these types of pain patch products.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan non-opioid pain patches market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Hisamitsu Pharmaceutical Co., Inc.
• Teikoku Seiyaku Co., Ltd.
• Nitto Denko Corporation
• Oishi Koseido
• Kyukyu Pharmaceutical Co., Ltd.
• Nichiban Co., Ltd.
• Takeda Pharmaceutical Co., Ltd.
• Daiichi Sankyo Co., Ltd.
• Eisai Co., Ltd.
• Pfizer Japan Inc.
• Other

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In September?2023, Teikoku Pharma USA announced positive topline results from a Phase?2 trial of its non?opioid pain patch TPU?006 (dexmedetomidine), showing reduced pain scores and lower opioid rescue use compared to placebo.

Market Segment

This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035. Decision Advisors has segmented the Japan Non-Opioid Pain Patches Market based on the below-mentioned segments:

Japan Non-Opioid Pain Patches Market, By Patch Type

• Lidocaine Patches
• Diclofenac Patches
• Capsaicin Patches
• Others

Japan Non-Opioid Pain Patches Market, By Technology

• Matrix Patches
• Reservoir Patches
• Others

FAQs

Q: What was the estimated size of the Japan Non-Opioid Pain Patches Market in 2024?

A: The market was estimated at USD 35.4 million in 2024.

Q: What is driving the growth of the Japan non-opioid pain patches market?

A: The market is driven by an aging population, preference for non-invasive treatments, and increased awareness of opioid-related risks.

Q: Which patch type held the largest revenue share in 2024?

A: Lidocaine patches accounted for the largest revenue market share in 2024.

Q: What technology segment led the market in 2024?

A: Matrix patches held the largest revenue market share in 2024 due to flexible API development and consistent drug release.

Q: Can you name a recent development in Japan’s non-opioid pain patch market?

A: In September 2023, Teikoku Pharma USA announced positive Phase?2 trial results for its TPU?006 patch, showing reduced pain scores and lower opioid rescue use.